NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Woodline Partners LP

Woodline Partners LP lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 108.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,430,782 shares of the company's stock after purchasing an additional 1,266,105 shares during the period. Woodline Partners LP owned about 2.63% of NewAmsterdam Pharma worth $62,471,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bain Capital Life Sciences Investors LLC increased its position in NewAmsterdam Pharma by 2.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock valued at $275,481,000 after acquiring an additional 245,197 shares during the period. RA Capital Management L.P. increased its position in NewAmsterdam Pharma by 9.7% in the 4th quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company's stock valued at $227,316,000 after acquiring an additional 781,000 shares during the period. Deerfield Management Company L.P. Series C increased its position in NewAmsterdam Pharma by 378.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock valued at $110,879,000 after acquiring an additional 3,412,590 shares during the period. Jennison Associates LLC increased its position in NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after acquiring an additional 2,978,263 shares during the period. Finally, Wellington Management Group LLP increased its position in NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after acquiring an additional 2,222,900 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper purchased 4,005 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, with a total value of $84,185.10. Following the purchase, the director now directly owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. The trade was a 0.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This trade represents a 90.91% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Trading Up 0.8%

NASDAQ NAMS opened at $19.03 on Tuesday. The business's 50 day moving average is $18.99 and its two-hundred day moving average is $21.28. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -10.12 and a beta of 0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The business had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. Equities analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Royal Bank of Canada restated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Needham & Company LLC dropped their price target on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Scotiabank boosted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Finally, UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research report on Monday, March 3rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $43.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Want to see what other hedge funds are holding NAMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma (NASDAQ:NAMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.